Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
Loading...
Embargo End Date
ICR Authors
Authors
Goggin, C
Stansfeld, A
Mahalingam, P
Thway, K
Smith, MJ
Huang, P
Jones, RL
Napolitano, A
Stansfeld, A
Mahalingam, P
Thway, K
Smith, MJ
Huang, P
Jones, RL
Napolitano, A
Document Type
Journal Article
Date
2022-07-26
Date Accepted
2022-06-24
Abstract
Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it as a lasting therapy in the management of early-stage and advanced disease in the first-line setting. Imatinib resistance inevitably develops, resulting in the need for further lines of therapy. Ripretinib is an orally administered switch-control tyrosine kinase inhibitor, specifically developed to target both primary and secondary KIT and PDGFRα resistance mutations. Herein, the authors discuss the molecular rationale, the preclinical evidence and the clinical use of ripretinib in the treatment of gastrointestinal stromal tumors in the advanced stages of disease.
Citation
Future Oncology, 2022, 18 (26), pp. 2967 - 2978
Source Title
Future Oncology
Publisher
TAYLOR & FRANCIS LTD
ISSN
1479-6694
eISSN
1744-8301
1744-8301
1744-8301
Collections
Research Team
Translational Sarcoma, Melanoma and Rare Tumour Surgery
Mol and Systems Oncology
Mol and Systems Oncology